用关法素作为三角神经阻塞的辅助剂增强疼痛缓解:来自pheWAS引导的随机对照研究的见解
Shelby E Meier1, Michael B Orr1, Matthew S Shotwell2
1Vanderbilt Institute for Clinical and Translational Research, Senior Scientific Research Project Manager.
Pain medicine (Malden, Mass.)
|May 6, 2025
概括
将guanfacine添加到利多卡因神经阻塞剂中,改善了三角神经疼痛患者的短期疼痛缓解. 这种α-2上腺素受体 (ADRA2) 激动剂在难以治疗的面部疼痛条件下显示出增强止痛的前景.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 疼痛管理 疼痛管理
背景情况:
- 三神经疼痛和神经病变会导致严重的,难以治疗的面部疼痛.
- 现象广泛关联研究 (PheWAS) 将α-2上腺素受体B (ADRA2B) 变体与增加三角神经疾病风险联系起来.
- ADRA2B是前突触终端上的G蛋白结合受体,这表明它是一个潜在的治疗点.
研究的目的:
- 为了调查是否添加guanfacine,一个ADRA2激动剂,常规的三角神经注射增强了疼痛缓解.
- 为了比较单独利多卡因与利多卡因加关法辛治疗三角神经疼痛的疗效.
主要方法:
- 进行了一项单中心,前性,随机,双盲,交叉试验.
- 患者接受了单独注射利多卡因或与250微克关法辛一起注射的利多卡因,向V2/V3三神经分支.
- 使用数值评分表 (NRS) 评估疼痛;使用PROMIS调查测量生活质量.
主要成果:
- 在注射后8小时内,在guanfacine + lidocaine组中,NRS疼痛评分明显较低 (p < 0.001).
- 从第1天到第14天的组之间没有观察到疼痛恢复时间,PROMIS结果或不良事件的显著差异.
- 在研究期间没有报告任何严重不良事件.
结论:
- 在利多卡因神经阻塞剂中添加250μg的guanfacine显著增强了短期止痛 (在8小时内).
- 当与神经阻塞一起使用时,guanfacine可能会改善三角神经疾病的疼痛缓解.
相关概念视频
01:25Analgesia and Pain Management
392
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
392
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
167
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
167
01:28Drugs Acting on Autonomic Ganglia: Blockers
918
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
918